Top Markets
Coin of the day
Fresenius SE & Co. KGaA Fresenius SE & Co. KGaA

Fresenius SE & Co. KGaA

FSNUY
Rangering i aksjer #183
Fresenius SE & Co. KGaA, a health care company, provides products and services... Fresenius SE & Co. KGaA, a health care company, provides products and services for dialysis, hospitals, and outpatient medical care. It operates through four segments: Fresenius Medical Care, Fresenius Kabi, Fresenius Helios, and Fresenius Vamed. The Fresenius Medical Care segment offers products and services for patients with chronic kidney failure. This segment provides dialyzers, hemodialysis machines, and related disposable products, as well as dialysis-related services. The Fresenius Kabi segment engages in the therapy and care of therapy and care ill patients. This segment offers IV drugs, including intravenously administered generic drugs for oncology, anesthetics, analgesics, anti-infectives, and critical care; parenteral and enteral nutrition products; infusion solutions and blood volume substitutes for infusion therapy; biosimilars, a biological medicine for autoimmune and oncology diseases; medical devices and disposal used to administer IV generic drugs, infusion therapies, and clinical nutrition products; and transfusion products for collection of blood components and corporeal therapies. The Fresenius Helios segment operates 90 hospitals, approximately 130 outpatient clinics, and 6 prevention centers in Germany; and 49 hospitals, 88 outpatient clinics, and approximately 300 risk prevention centers in Spain. This segment also provides services in the field of fertility treatments through 33 clinics and additional 39 sites across 10 countries on 3 continents. The Fresenius Vamed segment manages projects and offers services for hospitals and other health care facilities. This segment provides project development, planning, and turnkey construction services, as well as maintenance, technical management, and operational management services. The company was formerly known as Fresenius SE and changed its name to Fresenius SE & Co. KGaA in January 2011. Fresenius SE & Co. KGaA was founded in 1912 and is headquartered in Bad Homburg vor der Höhe, Germany.
Aksjekurs
$12.65
Markedsverdi
$114.00B
Endring (1 dag)
1.36%
Endring (1 år)
3.52%
Land
DE
Handel Fresenius SE & Co. KGaA (FSNUY)

Kategori

P/E-forhold for Fresenius SE & Co. KGaA (FSNUY)
P/E-forhold per July 2026 TTM: 15.42
Ifølge Fresenius SE & Co. KGaA sine siste finansielle rapporter og aksjekurs er selskapets nåværende P/E-forhold (TTM) 15.42. Ved slutten av 2023 hadde selskapet en P/E på -26.62.
P/E-forholdshistorikk for Fresenius SE & Co. KGaA fra 2002 til 2026
P/E-forhold ved slutten av hvert år
År P/E-forhold Endre
2026 (TTM) 15.42 -61.55%
2024 40.11 -250.69%
2023 -26.62 -347.86%
2022 10.74 -1.18%
2021 10.87 -12.06%
2020 12.36 -16.72%
2019 14.84 25.16%
2018 11.86 -40.46%
2017 19.91 -21.96%
2016 25.52 -3.60%
2015 26.47 20.88%
2014 21.90 10.82%
2013 19.76 21.32%
2012 16.29 85.50%
2011 8.78 4.03%
2010 8.44 19.22%
2009 7.08 -66.62%
2008 21.21 0.48%
2007 21.10 -10.70%
2006 23.63 253.85%
2005 6.68 10.06%
2004 6.07 -20.73%
2003 7.66 108.28%
2002 3.68 0.00%
P/E-forhold for lignende selskaper eller konkurrenter
Selskap P/E-forhold Forskjell i P/E-forhold Land
12.43 -19.39%
US
31.92 107.01%
SA
9.47 -38.57%
US
19.33 25.36%
CN
22.90 48.48%
US
Hvordan lese en P/E-ratio?

Pris/inntjening-forholdet (P/E) måler forholdet mellom aksjekursen og inntjening per aksje.
En lav men positiv P/E indikerer høy inntjening sammenlignet med nåværende verdsettelse, og kan tyde på at selskapet er undervurdert. En høy negativ (nær 0) P/E indikerer store tap.

Selskaper med P/E over 30 eller negativ betraktes vanligvis som "vekstaksjer", hvor investorer forventer vekst eller fremtidig lønnsomhet.

Selskaper med en positiv P/E under 10 anses vanligvis som "verdiaksjer", det vil si at selskapet allerede er lønnsomt, men har begrenset vekstpotensial.